Status:
UNKNOWN
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Amphetamine-Related Disorders
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
Detailed Description
The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.
Eligibility Criteria
Inclusion
- Healthy individuals with a body mass index between 18 and 30.
- Willing and able to give written consent.
- Must have a negative drug test
- Females must have a negative pregnancy test prior to study drug administration
- Must have no medical contraindications as determined by routine testing
Exclusion
- Please contact the site for more information
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00100074
Start Date
September 1 2004
End Date
April 1 2005
Last Update
January 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U of CA, San Francisco
San Francisco, California, United States, 94143